HealthExec January 5, 2023
Jessica Kania

Using VA healthcare records, a group of researchers found that veterans who received a third dose of Moderna (mRNA-1273) had fewer documented instances of COVID-19 infections, symptomatic infections, hospitalizations, ICU admissions, and death compared with those who received a third dose of Pfizer-BioNTech (BNT162b2).

The findings, published in the journal Nature Microbiology, used veterans’ health records to conduct a retroactive analysis representing two emulated “trials.” The first trial covered veterans vaccinated during a period representing both the Delta and Omicron waves (October 2021 through February 2022), with the following results:

Trial 1 (Delta and Omicron waves): Excess number of events over 16 weeks per 10,000 people

Documented infections: 45.4 (95% CI: 19.4, 84.7)

Symptomatic infections: 3.7 (95% CI: 2.2,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID, Survey / Study, Trends, VA / DoD
Related Articles:
Mpox Clade I in the U.S. Should Be a Wake-Up Call
Journalists Address HHS Under Trump, Rural PFAS Contamination, and Bird Flu
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
It's sick season. Here's how to protect yourself from norovirus, COVID-19, flu and RSV
China marks muted 5th anniversary of first COVID death

Share This Article